Literature DB >> 27792846

Population screening for spinal muscular atrophy: A mixed methods study of the views of affected families.

Felicity K Boardman1, Philip J Young2, Frances E Griffiths1.   

Abstract

Autosomal recessive conditions are a significant health burden with few treatments. Population carrier screening has been suggested as a means to tackle them. Little is known about the views of affected families despite the potential for direct impacts on them. Data are presented on attitudes among families affected by Spinal Muscular Atrophy (SMA) toward two population screening programs, pre-conception, and prenatal. Data were gathered through qualitative interviews (n = 36) and a survey (n = 337). Eighty-two survey participants had SMA and 255 were family members. The majority were in favor of screening (75%). Reasons for supporting pre-conception screening support were a belief that it would reduce SMA-related terminations and raise awareness of SMA in the population. For prenatal screening, reasons for support included a belief in the importance of informed decision-making and the need to reduce suffering. Key reasons for non-support of pre-conception screening included concerns about carrier stigmatization and social engineering. For prenatal screening, concerns focused on the collateral loss of high quality of life lives affected by SMA. This study highlights that those affected by SMA are predominantly in favor of screening, although pre-conception screening is most favored. While family members and adults with SMA had largely consistent views, perceptions varied according to the severity (type) of SMA, with those affected by SMA type II the least likely to support screening. These findings suggest that screening for SMA is a complex issue for affected families, underscoring the need to consider and include their views when planning and implementing screening programs.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  ethics; genetic screening; mixed methods; spinal muscular atrophy

Mesh:

Substances:

Year:  2016        PMID: 27792846     DOI: 10.1002/ajmg.a.38031

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  16 in total

Review 1.  How does the genomic naive public perceive whole genomic testing for health purposes? A scoping review.

Authors:  Isabella A Sherburn; Keri Finlay; Stephanie Best
Journal:  Eur J Hum Genet       Date:  2022-10-19       Impact factor: 5.351

2.  Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran.

Authors:  Zohreh Sharifi; Mohammad Taheri; Mohammad-Sadegh Fallah; Maryam Abiri; Fatemeh Golnabi; Hamideh Bagherian; Razieh Zeinali; Hossein Farahzadi; Marjan Alborji; Pardis Ghazizadeh Tehrani; Masoume Amini; Sadaf Asnavandi; Mehrdad Hashemi; Flora Forouzesh; Sirous Zeinali
Journal:  J Mol Neurosci       Date:  2021-01-22       Impact factor: 3.444

3.  Preconception expanded carrier screening: a focus group study with relatives of mucopolysaccharidosis type III patients and the general population.

Authors:  Thirsa Conijn; Ivy van Dijke; Lotte Haverman; Phillis Lakeman; Frits A Wijburg; Lidewij Henneman
Journal:  J Community Genet       Date:  2021-03-22

4.  The role of experiential knowledge within attitudes towards genetic carrier screening: A comparison of people with and without experience of spinal muscular atrophy.

Authors:  Felicity K Boardman; Philip J Young; Oliver Warren; Frances E Griffiths
Journal:  Health Expect       Date:  2017-07-13       Impact factor: 3.377

5.  Impairment Experiences, Identity and Attitudes Towards Genetic Screening: the Views of People with Spinal Muscular Atrophy.

Authors:  Felicity K Boardman; Philip J Young; Frances E Griffiths
Journal:  J Genet Couns       Date:  2017-06-30       Impact factor: 2.537

6.  Newborn genetic screening for spinal muscular atrophy in the UK: The views of the general population.

Authors:  Felicity K Boardman; Chloe Sadler; Philip J Young
Journal:  Mol Genet Genomic Med       Date:  2017-11-23       Impact factor: 2.183

7.  Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives.

Authors:  Michelle A Farrar; Kate A Carey; Sarah-Grace Paguinto; Georgina Chambers; Nadine A Kasparian
Journal:  BMJ Open       Date:  2018-05-24       Impact factor: 2.692

8.  Newborn screening for haemophilia: The views of families and adults living with haemophilia in the UK.

Authors:  Felicity K Boardman; Rachel Hale; Philip J Young
Journal:  Haemophilia       Date:  2019-02-28       Impact factor: 4.287

9.  Preventing lives affected by hemophilia: A mixed methods study of the views of adults with hemophilia and their families toward genetic screening.

Authors:  Felicity K Boardman; Rachel Hale; Raksha Gohel; Philip J Young
Journal:  Mol Genet Genomic Med       Date:  2019-03-05       Impact factor: 2.183

10.  Newborn screening for spinal muscular atrophy: The views of affected families and adults.

Authors:  Felicity K Boardman; Philip J Young; Frances E Griffiths
Journal:  Am J Med Genet A       Date:  2017-04-04       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.